The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug combination of ARRx (also known as AZD5312) plus enzalutamide in patients with metastatic <a target="_blank" href="https://clin.larvol.com/trial/NCT03300505">castration-resistant</a> prostate cancer.
This is a single dose-finding one-arm phase Ib/II trial to determine the <a target="_blank" href="https://clin.larvol.com/trial/NCT03300505">maximum tolerated dose</a> (MTD) from among three dose levels of ARRx in combination with a fixed dose of enzalutamide and to obtain a preliminary estimate of efficacy at this MTD, as measured by PSA response rate. Success for the trial is defined as finding a dose level that is likely to be both tolerable and effective.
The study was originally registered as a phase 1/ phase 2 study; however, the study was cancelled by the sponsor before opening the phase 2 portion.

The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug combination of ARRx (also known as AZD5312) plus enzalutamide in patients with metastatic [castration-resistant](https://clin.larvol.com/trial/NCT03300505) prostate cancer.

This is a single dose-finding one-arm phase Ib/II trial to determine the [maximum tolerated dose](https://clin.larvol.com/trial/NCT03300505) (MTD) from among three dose levels of ARRx in combination with a fixed dose of enzalutamide and to obtain a preliminary estimate of efficacy at this MTD, as measured by PSA response rate. Success for the trial is defined as finding a dose level that is likely to be both tolerable and effective.

The study was originally registered as a phase 1/ phase 2 study; however, the study was cancelled by the sponsor before opening the phase 2 portion.

ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer